Merck's latest earnings call revealed a mix of growth and pain points for the pharmaceutical giant.

Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates.

We recently published a list of Jim Cramer Discussed These 12 Stocks Recently. In this article, we are going to take a look ...

Merck & Co. (NYSE:MRK) is a prominent American multinational pharmaceutical company many investors know for its brand-name ...

Merck plans to stop a late-stage study testing its drug to treat pulmonary arterial hypertension (PAH) ahead of time based on ...

Merck’s full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...

Merck shares tumbled Tuesday morning after the drugmaker's soft outlook outweighed fourth-quarter revenue and adjusted profits topping expectations.

Financial writer advises caution on investing in Merck & Co., Inc. due to negative sentiment and potential price declines. Click for more on MRK Q4 earnings.

Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...

Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.

Financial writer recommends Merck & Co., Inc. as a strong healthcare stock despite recent challenges, citing strong potential ...

Revenue and adjusted earnings, however, managed to top expectations. Sales of a few Merck drugs were hit by lower international demand and lower pricing in the U.S., the company said. Merck shares ...